Personalized cancer vaccines

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

49 papers

Active filtersClassification:Supporting

Showing 13-24 of total 49 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Construction of a Neoantigen Prognostic Model for Gastric Adenocarcinoma Based on Multi-Omics Data Mining and the Design of mRNA Vaccines and Targeted Drugs.

Liang J; Xie Z; Sun Y; Tang Y; Gul S; Qi Q; Pang J; Chen Y; Wang H; Zhang J; Tang W; Zhou X

2026PubMedSupporting evidence

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

Leta EM; Syed S; Binegde GN; Gu D; Xiong J; Wang F

Jan 1, 2026International immunopharmacology

2026PubMedSupporting evidence

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

Leta EM; Syed S; Binegde GN; Gu D; Xiong J; Wang F

Jan 1, 2026International immunopharmacology

2026PubMedSupporting evidence

Targeting splicing-derived neoantigens for precision cancer immunotherapy.

Tang M; Grimes HL; Salomonis N

Jan 1, 2026Frontiers in immunology

2026PubMedSupporting evidence

Manganese-doped zinc oxide Nano-agonists activating the cGAS-STING pathway to potentiate anti-tumor immunotherapy and reprogram the immunosuppressive tumor microenvironment.

Hou Z; Xu H; Zhou D; Fing C; Li S

Jan 1, 2026Biomaterials advances

2026PubMedSupporting evidence

Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.

Chen L; Song MH; Jin M; Jin H; Gong L; Feng J; Hao Y; Shao H; Gong X; Gao Z; Yang Q; Huang W

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society

2026PubMedSupporting evidence

Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.

Chen L; Song MH; Jin M; Jin H; Gong L; Feng J; Hao Y; Shao H; Gong X; Gao Z; Yang Q; Huang W

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society

2026PubMedSupporting evidence

Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without neoantigen identification.

Wang X; Deng D; He Y; Wang X; Dai R

Jan 1, 2026International immunopharmacology

2026PubMedSupporting evidence

Self-Enhancing Photodynamic / Immunotherapy via a MOF Nanoplatform for Combined STING Activation and Immune Checkpoint Blockade.

Liu B; Zhang J; Xu W; Liu Y; Wu N; Peng H; Li H; Sun Z; Chu H

Jan 1, 2026Advanced healthcare materials

2026PubMedSupporting evidence

Nanomedicine strategies for remodeling the solid tumor microenvironment: stromal targeting, hypoxia modulation, and photodynamic immunotherapy.

Rauf MA; Luong D; Shah F; Iyer AK

Jan 1, 2026Frontiers in oncology

2026PubMedSupporting evidence

Antigen presentation requirements for effective cDC1-based cancer immunotherapy.

Pineda JE; Minowa T; Shen L; Zhou Y; Dyevoich A; Patel B; Schneider SM; Keshari S; Saha A; Riba MN; Wang J; Watowich SS; Gubin MM

Jan 1, 2026Journal of immunology (Baltimore, Md. : 1950)

2026PubMedSupporting evidence

Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.

Xu W; Liu S; Sun L; Bi Y; Lin Z; Wang T; Ren X; An R

Jan 1, 2026Oncogene